Johnson & Johnson Profit Margin 2010-2025 | JNJ

Current and historical gross margin, operating margin and net profit margin for Johnson & Johnson (JNJ) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Johnson & Johnson net profit margin as of March 31, 2025 is 24.42%.
Johnson & Johnson Annual Profit Margins
Johnson & Johnson Quarterly Profit Margins
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $364.111B $88.821B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $717.806B 55.04
AbbVie (ABBV) United States $325.054B 17.92
Novo Nordisk (NVO) Denmark $288.862B 19.04
Roche Holding AG (RHHBY) Switzerland $248.931B 0.00
Novartis AG (NVS) Switzerland $231.500B 13.22
Merck (MRK) United States $190.989B 9.76
Sanofi (SNY) France $130.557B 12.48
Pfizer (PFE) United States $129.797B 7.11
Bayer (BAYRY) Germany $25.032B 5.10
Innoviva (INVA) United States $1.166B 12.22